Dr. Philip D. Bonomi has researched and practiced medical oncology for more than 20 years. He focuses on cancers of the internal organs, mainly the lungs. One focus area of his research is pleural mesothelioma, a cancer of the lung linings.

Throughout his career, Dr. Bonomi has focused on improving cancer detection and diagnosis.

Dr. Bonomi’s Professional History

Dr. Philip D. Bonomi attended medical school at the University of Illinois College of Medicine. After receiving his degree, Dr. Bonomi began a residency at Geisinger Medical Center in Pennsylvania. His focus at Geisinger Medical Center was internal medicine.

After completing that program in 1975, he began a fellowship in medical oncology. Dr. Bonomi completed his fellowship at Rush-Presbyterian St. Luke’s Medical Center.

Now, he continues to work as a medical oncologist at Rush Medical Center in Chicago, Illinois. His areas of expertise include lung cancer and mesothelioma. He has served as the director of the division of Hematology and Oncology at Rush University Cancer Center.

Dr. Bonomi also teaches at Rush University. He is The Alice Pirie Wirtz Professor of Medical Oncology.

He has more than 20 years of clinical experience.

Clinical Interests and Research

Dr. Bonomi is an accomplished medical oncologist. His main fields of interest include lung cancers and internal medicine.

Dr. Bonomi’s Medical Areas of Interest

• Internal medicine
• Lung cancer
• Medical oncology
• Mesothelioma
• Thoracic cancers
• Thymoma and thymic cancer

Dr. Bonomi’s research concerns diagnosing and treating cancer. He has authored or co-authored more than 150 research papers.

One of his main research interests is small-cell lung cancer treatment and detection. Recently, his research included using liquid biopsies as a minimally invasive option for lung cancer patients.

Selected Publications

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. Journal of Thoracic Oncology. February 2018;13(2):165-183. doi: 10.1016/j.jtho.2017.11.111

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. Journal of Clinical Oncology. February 2019;37(4):278-285. doi: 10.1200/JCO.18.01585

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. September 2018;13(9):1393-1399. doi: 10.1016/j.jtho.2018.05.002

Dr. Bonomi’s Accolades

Dr. Bonomi has been recognized by several institutions throughout his career in medicine.

• America’s Top Doctor for Cancer (2005, 2006,2007, 2008, 2009, 2010, 2011, 2012, 2013) – Castle Connolly
• Certification in Internal Medicine – American Board of Internal Medicine
• Certification in Medical Oncology – American Board of Internal Medicine
• Chicago Top Doctor (2004, 2006, 2008, 2010, 2012, 2014, 2016, 2018, 2019, 2020) – Chicago Magazine